Total Funding
10
Total FundingPost-IPO Debt raised
Growth Score
pts
Heat Score
5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
3488139
Ocata Therapeutics is a clinical stage biotechnology company that develops new therapies in the field of regenerative medicine.
Acquired by 
Astellas Pharma
Dr. Robert Lanza: Chief Scientific OfficerPast Role: Ocata Therapeutics, Various roles
Kathy Singh: Director Program Management
About the Company
Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s
intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs.
